Categories
Research Insights
NIH: RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
This initiative promotes fundamental studies in the emerging area of RNA modifications that underlie the oncogenic process, focusing on the central role of RNA modifications in translational reprogramming of cancer cells.
Amount: $4,907,500
Due Date: 10/05/2024 (LOI); 11/04/2024 (Full Proposal)